本帖最后由 老马 于 2012-1-13 21:20 编辑 7 m8 J7 Y8 M# t5 j
2 O- c" P# Y9 z' B爱必妥和阿瓦斯丁的比较
( l1 t" i2 \) P3 ^$ w* v
$ ^" i# h5 V- o' p; D4 V
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
9 l8 J; Y% _3 {" [- q) |; g' e: M
* N6 l, |) e. s* D+ D
@( ]! u9 n/ c m# ~) l1 D
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/4 v/ c* h/ l+ s5 {0 G: ?
==================================================) w3 r1 Z7 h$ X0 E( G' O6 Y
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
' _1 s+ E6 K" FPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
" u: M2 w! N' x5 mResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
0 l# R( D6 w* L, `
|